GO:0042953 lipoprotein transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042953 (lipoprotein transport) describes the directed movement of conjugated, water-soluble proteins whose nonprotein group is a lipid, into, out of, or within a cell, or between cells, via transporters or pores.
• In Gram-negative bacteria, lipoprotein transport is an essential envelope-sorting process driven by the LolCDE ABC transporter, which extracts lipoproteins from the inner membrane and hands them to LolA for delivery to the outer membrane.
• The Lol pathway is a validated antibacterial target because lipoprotein transport is essential for outer membrane integrity and bacterial viability.
• In humans, lipoprotein transport underpins reverse cholesterol transport, the process by which HDL carries cholesterol from peripheral tissues to the liver for excretion.
• Age-related decline in HDL-mediated reverse cholesterol transport is associated with reduced cardiovascular protection, linking lipoprotein transport to aging and atherosclerosis.
• Genetic variation in lipoprotein transport and cholesterol absorption pathways, such as LIMA1 variants, can lower plasma LDL cholesterol and modulate intestinal cholesterol uptake.
Description
GO:0042953, lipoprotein transport, is a biological process defined as the directed movement of any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. This term captures a fundamental trafficking problem: lipids are hydrophobic and cannot freely diffuse through aqueous compartments, so cells package them into lipoproteins and move these particles with dedicated protein machinery. In bacteria, lipoprotein transport is a membrane-sorting problem solved by the Lol system, which moves lipidated proteins from the inner membrane to the outer membrane. In humans, lipoprotein transport is central to systemic lipid homeostasis, including the reverse cholesterol transport pathway that returns cholesterol from peripheral tissues to the liver. Because defects in lipoprotein transport contribute to infection susceptibility, dyslipidemia, and cardiovascular disease, the process is a major focus of both antibacterial and cardiometabolic research.
lipoprotein transport At A Glance
| GO ID | GO:0042953 |
|---|---|
| GO term | lipoprotein transport |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Directed movement of lipid-conjugated, water-soluble proteins into, out of, or within cells, or between cells, via transporters or pores |
| Representative bacterial machinery | LolCDE ABC transporter, LolA, LolB, Lpt pathway crosstalk |
| Representative human pathway | HDL-mediated reverse cholesterol transport |
| Disease relevance | Bacterial envelope integrity, atherosclerosis, dyslipidemia, age-related loss of reverse cholesterol transport |
| Research methods | Structural biology, bacterial genetics, lipoprotein profiling, CRISPR screens, bioinformatics |
What Is GO:0042953?
Lipoprotein transport (GO:0042953) is the directed movement of a conjugated, water-soluble protein whose nonprotein group is one or more lipids, into, out of, or within a cell, or between cells, using an agent such as a transporter or pore. In practice, this includes bacterial lipoprotein sorting across the cell envelope and eukaryotic lipoprotein particle trafficking in plasma and tissues.
Why Is lipoprotein transport Important in Cell Biology?
Lipoprotein transport is important because it solves the biophysical problem of moving lipid-associated cargo through aqueous and membrane environments, and because failure of this process has direct consequences for cell envelope integrity in bacteria and for cardiovascular health in humans. In Gram-negative bacteria, lipoprotein transport by LolCDE is essential for viability, making it a high-value antibacterial target. In humans, reverse cholesterol transport mediated by HDL is a protective pathway against atherosclerosis, and its activity declines with age. Genetic and physiological studies of cholesterol absorption and lipoprotein handling continue to identify targets for lipid-lowering strategies.
• Essential for Gram-negative bacterial outer membrane biogenesis and viability.
• Provides a validated target space for new antibiotics against multidrug-resistant bacteria.
• Underpins HDL-mediated reverse cholesterol transport, a key atheroprotective pathway.
• Declines with age, contributing to reduced cardiovascular protection in older adults.
• Connects to systemic glucose and lipid metabolism regulation in health and disease.
• Modulates intestinal cholesterol absorption and plasma LDL cholesterol levels.
• Involves mechanistically distinct transporters and chaperones that can be dissected genetically.
• Offers a tractable system for structural and mechanistic studies of ABC transporters.
• Links membrane protein sorting to bacterial pathogenesis and host interaction.
• Provides biomarkers and pathways relevant to cardiometabolic drug discovery.
What Happens During lipoprotein transport?
Substrate recognition and extraction at the inner membrane
In simple terms: The transporter first grabs the lipidated protein from the inner membrane.
In Gram-negative bacteria, lipoprotein transport begins when the LolCDE ABC transporter recognizes the lipid moiety of inner membrane lipoproteins and extracts them from the bilayer in an ATP-dependent manner. Structural and biochemical studies show that LolCDE uses a conserved substrate-binding cavity and a LolE interaction surface to engage the lipidated cargo, ensuring that only properly modified lipoproteins enter the pathway. This step is the committed step of lipoprotein transport and is essential for downstream envelope sorting.
Chaperone handoff to LolA
In simple terms: A carrier protein picks up the lipoprotein and ferries it across the periplasm.
After extraction, the lipoprotein is transferred to the periplasmic chaperone LolA, which shields the lipid moiety from the aqueous periplasm and delivers it to the outer membrane receptor LolB. Recent structures of liganded LolCDE reveal a common substrate-LolE interaction that guides this handoff, explaining how the transporter and chaperone cooperate to maintain directionality. This step ensures that lipoproteins do not mislocalize to the inner membrane.
Outer membrane insertion and sorting
In simple terms: The lipoprotein is inserted into the outer membrane at its correct destination.
LolB accepts the lipoprotein from LolA and inserts it into the outer membrane, completing the transport cycle. Crosstalk between the Lpt and Lol pathways further sorts surface lipoproteins, integrating lipoprotein transport with lipopolysaccharide transport and outer membrane homeostasis. This coordination is critical because both pathways compete for and share envelope space and machinery.
Eukaryotic lipoprotein transport and reverse cholesterol transport
In simple terms: In humans, lipoproteins carry cholesterol and lipids through the blood to and from tissues.
In eukaryotes, lipoprotein transport is exemplified by HDL-mediated reverse cholesterol transport, in which HDL particles accept cholesterol from peripheral cells and deliver it to the liver for excretion. This process depends on the structural and functional properties of HDL and its associated proteins, and its efficiency is a major determinant of cardiovascular risk. Age-associated decreases in reverse cholesterol transport activity have been documented, linking lipoprotein transport capacity to aging.
Regulation by metabolic and genetic factors
In simple terms: The body adjusts lipoprotein transport based on metabolic state and genetic makeup.
Lipoprotein transport is regulated by systemic metabolic signals and genetic variation. Glucose and lipid metabolism are coordinately regulated in health and disease, influencing lipoprotein production and clearance. Genetic variants such as LIMA1 can alter intestinal cholesterol absorption and plasma LDL cholesterol, demonstrating that lipoprotein transport pathways are modifiable by human genetics. These regulatory inputs determine overall lipid flux and disease susceptibility.
Key Genes Involved in GO:0042953 lipoprotein transport
The following genes and proteins are central to lipoprotein transport across bacterial and eukaryotic systems, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LolCDE | ABC transporter that extracts lipoproteins from the inner membrane | Essential bacterial lipoprotein transport; antibacterial target |
| LolA | Periplasmic chaperone that carries lipoproteins to the outer membrane | Mechanistic studies of handoff and directionality |
| LolB | Outer membrane receptor that inserts lipoproteins | Completes the Lol transport cycle |
| LolE | Subunit of LolCDE with substrate interaction surface | Structural basis of substrate recognition |
| Lpt pathway components | Lipopolysaccharide transport machinery that crosstalks with Lol | Surface lipoprotein sorting and envelope homeostasis |
| APOA1 | Major HDL apolipoprotein | HDL structure and reverse cholesterol transport |
| ABC1/ABCA1 | Cholesterol efflux transporter to lipid-poor apolipoproteins | HDL biogenesis and reverse cholesterol transport |
| CETP | Cholesteryl ester transfer protein | Modulates HDL cholesterol metabolism |
| LCAT | Lecithin-cholesterol acyltransferase | HDL maturation and reverse cholesterol transport |
| SR-BI | HDL receptor mediating selective cholesterol uptake | Liver cholesterol clearance |
| LIMA1 | Regulates intestinal cholesterol absorption and LDL cholesterol | Genetic modulation of lipoprotein transport |
| NPC1L1 | Intestinal cholesterol uptake transporter | Cholesterol absorption and LDL levels |
| LDLR | LDL receptor mediating lipoprotein uptake | Plasma LDL clearance |
| PCSK9 | Regulates LDL receptor degradation | Lipid-lowering drug target |
| SREBP | Transcription factor controlling lipid synthesis and uptake | Metabolic regulation of lipoprotein transport |
| PPARs | Nuclear receptors regulating lipid metabolism | Coordination of glucose and lipid homeostasis |
| ApoB | Structural apolipoprotein of LDL and VLDL | Lipoprotein assembly and secretion |
How Is lipoprotein transport Regulated?
Lipoprotein transport is regulated at multiple levels. In bacteria, the Lol pathway is tightly coupled to outer membrane biogenesis and responds to envelope stress through crosstalk with the Lpt pathway. In humans, systemic glucose and lipid metabolism coordinately regulate lipoprotein production, remodeling, and clearance, with transcription factors such as SREBP and nuclear receptors such as PPARs controlling the expression of key genes. HDL-mediated reverse cholesterol transport is modulated by apolipoproteins, enzymes such as LCAT and CETP, and receptors such as SR-BI, and its activity declines with age. Genetic variation, including LIMA1 variants, further tunes intestinal cholesterol absorption and plasma LDL cholesterol.
lipoprotein transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LolCDE | Gram-negative bacterial infection; essential envelope biogenesis | Conditional knockout in E. coli; point mutations in ATPase domain |
| LolA/LolB | Bacterial lipoprotein sorting defects | Knockout and tagged knock-in for localization studies |
| LIMA1 | Dyslipidemia; reduced intestinal cholesterol absorption | Knock-in of human variant in mouse; overexpression in intestinal cells |
| ABCA1 | Tangier disease; defective HDL biogenesis | Knockout and point mutation models in cell lines |
| SR-BI | Altered HDL clearance and atherosclerosis | Knockout and overexpression in hepatocytes |
Bacterial infections and antibiotic resistance
Lipoprotein transport is essential for Gram-negative bacterial outer membrane integrity, and inhibition of LolCDE impairs viability, making the pathway a promising antibacterial target. Crosstalk between Lpt and Lol pathways is important for surface lipoprotein sorting and bacterial pathogenesis, so disrupting this coordination could attenuate virulence.
Atherosclerosis and cardiovascular disease
HDL-mediated reverse cholesterol transport protects against atherosclerosis by removing excess cholesterol from peripheral tissues. Age-associated decreases in reverse cholesterol transport activity reduce this protection and are linked to increased cardiovascular risk in older adults. Modulating lipoprotein transport is therefore a therapeutic strategy for dyslipidemia and atherosclerosis.
Dyslipidemia and metabolic disease
Genetic and physiological regulation of lipoprotein transport influences plasma LDL cholesterol and intestinal cholesterol absorption. LIMA1 variants that reduce LDL cholesterol and cholesterol absorption illustrate how lipoprotein transport genes can be targeted to treat dyslipidemia. Coordinated regulation of glucose and lipid metabolism also means that metabolic diseases such as diabetes can perturb lipoprotein transport.
From lipoprotein transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is LolCDE essential for bacterial viability? | Conditional knockout or CRISPR interference in E. coli |
| How does LolE recognize lipoprotein substrates? | Point mutations in substrate-binding residues followed by structural analysis |
| Does a human LIMA1 variant reduce cholesterol absorption? | Knock-in mouse or overexpression in intestinal epithelial cells |
| Where does LolA localize during transport? | Tagged knock-in with fluorescent protein for live imaging |
| Can ABCA1 overexpression increase reverse cholesterol transport? | Overexpression cell model with cholesterol efflux assays |
| What genes regulate lipoprotein transport in macrophages? | Genome-wide CRISPR knockout library screening |
How to Study the lipoprotein transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | Three-dimensional structure of transporter-substrate complexes | Mechanistic studies of LolCDE |
| Bacterial genetics (KO, point mutants) | Essentiality and sorting defects | Lol pathway function |
| Lipoprotein profiling (MS) | Abundance and localization of lipoproteins | Envelope sorting |
| Cholesterol efflux assay | HDL-mediated cholesterol removal from cells | Reverse cholesterol transport |
| Reverse cholesterol transport measurement | In vivo flux of cholesterol to liver | Atherosclerosis models |
| CRISPR knockout screen | Genes required for lipoprotein transport | Regulator discovery |
| RNA-seq | Transcriptional changes in lipid metabolism genes | Pathway regulation |
| Bioinformatics network analysis | Pathway crosstalk and candidate prioritization | Data integration |
Structural biology of transport complexes
Cryo-electron microscopy and X-ray crystallography have revealed the architecture of LolCDE and its substrate-bound states, providing mechanistic insight into lipoprotein recognition and transport. These methods are essential for defining how ATP binding and hydrolysis drive conformational changes that extract lipoproteins from the inner membrane.
Bacterial genetics and envelope assays
Genetic knockouts, conditional mutants, and point mutations in Lol components allow researchers to test essentiality and sorting defects. Envelope fractionation and lipoprotein profiling by mass spectrometry can quantify mislocalization and pathway flux.
Lipoprotein profiling and cholesterol flux assays
In eukaryotic systems, HDL subfraction analysis, cholesterol efflux assays, and reverse cholesterol transport measurements in cells and animal models quantify lipoprotein transport activity. These assays are used to test genetic variants and therapeutic interventions.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout screens combined with pathway enrichment and network analysis can identify novel regulators of lipoprotein transport. Bioinformatics integration of transcriptomic and lipidomic data helps prioritize candidate genes for functional validation.
How CRISPR Can Be Used to Study GO:0042953 lipoprotein transport
Knockout
CRISPR knockout of LolCDE components in Gram-negative bacteria can be used to test essentiality, often with inducible complementation systems. In human cells, knockout of ABCA1 or SR-BI disrupts reverse cholesterol transport and provides a clean background for rescue experiments.
Point Mutation
Point mutations in LolE substrate-binding residues or in the ATPase domain of LolCDE can dissect substrate recognition and energy coupling without abolishing protein expression. In LIMA1, knock-in of disease-associated variants can test their effect on cholesterol absorption.
Knock-in
Tagged knock-in of LolA or LolB with fluorescent or affinity tags enables live-cell imaging and proteomic analysis of lipoprotein transport intermediates. Knock-in of human LIMA1 variants into mouse models can validate their lipid-lowering effects.
Overexpression
Overexpression of ABCA1 or APOA1 in cell models boosts HDL biogenesis and reverse cholesterol transport, providing a gain-of-function system to study transport capacity. Overexpression of Lol components can also be used to probe stoichiometry and pathway saturation.
How EDITGENE Supports lipoprotein transport Research
Researchers studying lipoprotein transport-related genes often need to determine whether a candidate gene is causally involved in lipid trafficking, bacterial envelope integrity, or reverse cholesterol transport. Establishing causality requires precise genetic perturbation, which is where EDITGENE's CRISPR services can accelerate discovery.
Contact EDITGENE today to design your custom CRISPR model for lipoprotein transport research.
Frequently Asked Questions About lipoprotein transport
What is lipoprotein transport GO:0042953?
GO:0042953 is the biological process of directed movement of conjugated, water-soluble proteins with lipid nonprotein groups into, out of, or within cells, or between cells, via transporters or pores.
What genes are involved in lipoprotein transport?
Key genes include LolCDE, LolA, LolB in bacteria, and APOA1, ABCA1, CETP, LCAT, SR-BI, LIMA1, and LDLR in humans.
How does the Lol pathway transport lipoproteins?
LolCDE extracts lipoproteins from the inner membrane, LolA carries them across the periplasm, and LolB inserts them into the outer membrane.
Why is lipoprotein transport important for bacteria?
It is essential for outer membrane biogenesis and viability, making it a target for new antibiotics.
What is reverse cholesterol transport?
It is the HDL-mediated movement of cholesterol from peripheral tissues to the liver for excretion, a key atheroprotective process.
Does lipoprotein transport change with age?
Yes, HDL-mediated reverse cholesterol transport activity decreases with age, reducing cardiovascular protection.
What diseases are linked to lipoprotein transport defects?
Bacterial infections, atherosclerosis, dyslipidemia, and metabolic disorders are linked to defects in lipoprotein transport.
How can CRISPR be used to study lipoprotein transport?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of transport genes and pathways.
What methods study lipoprotein transport?
Structural biology, bacterial genetics, cholesterol efflux assays, lipoprotein profiling, and CRISPR screens are commonly used.
What is the role of LIMA1 in lipoprotein transport?
LIMA1 variants can reduce intestinal cholesterol absorption and lower plasma LDL cholesterol.
Conclusion
GO:0042953 lipoprotein transport is a fundamental biological process that spans bacterial envelope biogenesis and human systemic lipid homeostasis. Mechanistic studies of the Lol pathway have revealed how ABC transporters and chaperones cooperate to sort lipoproteins, providing a blueprint for antibacterial development. In humans, reverse cholesterol transport and its genetic regulation are central to cardiovascular health and disease. Continued research using CRISPR models and multi-omics approaches will further clarify how lipoprotein transport can be therapeutically modulated.
References
- 1. Qiao W et al.. 2024. Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE.. Signal Transduct Target Ther 9(1):354 PMID: 39725716
- 2. Chen L et al.. 2019. Regulation of glucose and lipid metabolism in health and disease.. Sci China Life Sci 62(11):1420-1458 PMID: 31686320
- 3. Lund-Katz S et al.. 2010. High density lipoprotein structure-function and role in reverse cholesterol transport.. Subcell Biochem 51:183-227 PMID: 20213545
- 4. Hersberger M et al.. 2005. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.. Handb Exp Pharmacol PMID: 16596814
- 5. Berrougui H et al.. 2009. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity.. Rejuvenation Res 12(2):117-26 PMID: 19405812
- 6. Szewczyk P et al.. 2026. Liganded LolCDE structures reveal a common substrate-LolE interaction guiding bacterial lipoprotein transport.. Proc Natl Acad Sci U S A 123(4):e2520579123 PMID: 41557797
- 7. Luo Q et al.. 2025. Surface lipoprotein sorting by crosstalk between Lpt and Lol pathways in gram-negative bacteria.. Nat Commun 16(1):4357 PMID: 40348743
- 8. Zhang YY et al.. 2018. A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption.. Science 360(6393):1087-1092 PMID: 29880681
